Rising Indian NCD Burden And Urbanization Will Transform Oncology Care
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 7 Analysts
Published
12 Jul 25
Updated
08 Aug 25
AnalystHighTarget's Fair Value
₹842.04
19.1% undervalued intrinsic discount08 Aug
₹681.35
1Y
92.0%7D
11.5%